Memtin
Our flagship asset, Memtin is a 16kDa biologic and has a well-defined and de-risked path to Phase 2. We anticipate starting a Phase 2 with Alzheimer’s patients in approximately 1 year form securing funding. Accelerated approval may allow conditional marketing approval after a positive Phase 2 trial.
NT1 and NT2
NT1 and NT2 are small peptides that block the PS1/CLIP-170 interaction and as such could ultimately become valuable preventative therapies for early-onset familial AD cases. These compounds are just completing discovery stage, and there are no known competitors.
Screen A and Screen B
Neurotez has developed two screening platforms that can become the basis for the discovery and identification of new molecular entities that are in the intersection of metabolic pathways and neurodegenerative pathways (Screen A) or can be identified as a binding partner of a specific protein target (Screen B)